AMPHOTERICIN B IN “MUCORMYCOSIS” – THE UNPRECEDENTED SURGE OF PANDEMIC
Celcy S.*, Bera Joseph, Monika Narayan, Nahid, Sreelakshmi K.G. and L. Britto Duraisingh
Purpose: Rhino orbital cerebral mucormycosis and use of amphotericin B in times of existing covid-19 pandemic. Aim: The aim of the study is to collect and document the cases of post covid rhino-orbital cerebral mucormycosis and also to observe and analyze the usage of amphotericin B at our institution. Method: This is a prospective, observational study. It was carried out at the tertiary care hospital from May 2021- August 2021. All patients of biopsy- proven Rhino-orbital mucormycosis were enrolled in the study. A minimum of 15 days follow-up was done for each patient. During the course of intravenous Amphotericin B, were analyzed by framing a checklist. Result: Seven patients were seen with the mean age of years. The major risk factors included are COVID-19 positivity (100%) with concomitant steroid using (57.14%) and uncontrolled diabetes mellitus (71.42%). Intravenous Amphotericin B was given to all patients for an average 7 days. Six patients were stable and were alive on follow-up. Mortality was seen in one patient. Conclusion: Mucormycosis is a rare condition which can still be fatal .A combination of surgical debridement plus intravenous Amphotericin B therapy, is acceptable in the management and has less morbidity rate.
Keywords: Post-covid Mucormycosis, Amphotericin-B, Rhino-Orbital Cerebral Mucormycosis.
[Full Text Article]